These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 15069050)
1. Postmenopausal estrogen for treatment of hot flashes: clinical applications. Nelson HD JAMA; 2004 Apr; 291(13):1621-5. PubMed ID: 15069050 [TBL] [Abstract][Full Text] [Related]
2. Commonly used types of postmenopausal estrogen for treatment of hot flashes: scientific review. Nelson HD JAMA; 2004 Apr; 291(13):1610-20. PubMed ID: 15069049 [TBL] [Abstract][Full Text] [Related]
3. Hormone therapy update. How to make sense of the new recommendations on postmenopausal hormone therapy. Harv Womens Health Watch; 2013 Mar; 20(7):3. PubMed ID: 23862210 [No Abstract] [Full Text] [Related]
4. Hormone therapy: a new consensus. Harv Womens Health Watch; 2012 Oct; 20(2):8. PubMed ID: 23193635 [No Abstract] [Full Text] [Related]
6. Postmenopausal hormone therapy: have HERS2 and WHI given us any new information? Fylstra DL J S C Med Assoc; 2002 Dec; 98(8):299-304. PubMed ID: 12532655 [TBL] [Abstract][Full Text] [Related]
7. Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Women: US Preventive Services Task Force Recommendation Statement. ; Grossman DC; Curry SJ; Owens DK; Barry MJ; Davidson KW; Doubeni CA; Epling JW; Kemper AR; Krist AH; Kurth AE; Landefeld CS; Mangione CM; Phipps MG; Silverstein M; Simon MA; Tseng CW JAMA; 2017 Dec; 318(22):2224-2233. PubMed ID: 29234814 [TBL] [Abstract][Full Text] [Related]
8. Hormone therapy: the next chapter. Is it time to rewrite the book on postmenopausal hormone use? Harv Womens Health Watch; 2011 Mar; 18(7):1-3. PubMed ID: 21526525 [No Abstract] [Full Text] [Related]
12. Beyond hot flashes: Exploring the role of estrogen therapy in postmenopausal women for myocardial infarction prevention and recovery. Choradia A; Bai K; Soni S; Nguyen N; Adhikari S; Kaur Rahul D; Gupta R Biomol Biomed; 2024 Jan; 24(1):4-13. PubMed ID: 37650466 [TBL] [Abstract][Full Text] [Related]
13. Economic impact of Tibolone compared with Continuous-Combined Hormone Replacement Therapy in the management of climacteric symptoms in postmenopausal women. Diaby V; Perreault S; Lachaine J Maturitas; 2007 Oct; 58(2):138-49. PubMed ID: 17870259 [TBL] [Abstract][Full Text] [Related]
14. Hormone replacement therapy in the post-Women's Health Initiative era. Report a a meeting held in Funchal, Madeira, February 24-25, 2003. Burger H Climacteric; 2003 May; 6 Suppl 1():11-36. PubMed ID: 12945798 [TBL] [Abstract][Full Text] [Related]
15. Transition from estrogen-progestin to raloxifene in postmenopausal women: effect on vasomotor symptoms. Gordon S; Walsh BW; Ciaccia AV; Siddhanti S; Rosen AS; Plouffe L Obstet Gynecol; 2004 Feb; 103(2):267-73. PubMed ID: 14754694 [TBL] [Abstract][Full Text] [Related]
16. Hormone replacement therapy in postmenopausal women. Yasui T; Uemura H; Takikawa M; Irahara M J Med Invest; 2003 Aug; 50(3-4):136-45. PubMed ID: 13678382 [TBL] [Abstract][Full Text] [Related]
17. Oestrogen replacement in postmenopausal women. Sassarini J; Lumsden MA Age Ageing; 2015 Jul; 44(4):551-8. PubMed ID: 26070875 [TBL] [Abstract][Full Text] [Related]
18. Invited Commentary: Hormone therapy risks and benefits--The Women's Health Initiative findings and the postmenopausal estrogen timing hypothesis. Banks E; Canfell K Am J Epidemiol; 2009 Jul; 170(1):24-8. PubMed ID: 19468078 [TBL] [Abstract][Full Text] [Related]